

House Bill 963 (AS PASSED HOUSE AND SENATE)

By: Representatives Parrish of the 158th, Stephens of the 164th, and Burchett of the 176th

A BILL TO BE ENTITLED
AN ACT

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
2 controlled substances, so as to change certain provisions relating to Schedule I controlled
3 substances and Schedule IV controlled substances; to change certain provisions relating to
4 the definition of dangerous drugs; to provide an effective date; to provide for related matters;
5 to repeal conflicting laws; and for other purposes.

6 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

7 **SECTION 1.**

8 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
9 substances, is amended in paragraph (1) of Code Section 16-13-25, relating to Schedule I
10 controlled substances, by revising subparagraph (K) and by adding a new subparagraph to
11 read as follows:

12 "(K) ~~Reserved~~ Brorphine;"

13 "(UU) Tianeptine;"

14 **SECTION 2.**

15 Said chapter is further amended in paragraph (3) of Code Section 16-13-25, relating to
16 Schedule I controlled substances, by revising subparagraphs (KK) and (LL) as follows:

17 "(KK) ~~Reserved~~ Para-methoxymethamphetamine (PMMA);

18 (LL) ~~Reserved~~ 4,4'-dimethylaminorex;"

19 **SECTION 3.**

20 Said chapter is further amended in paragraph (4) of Code Section 16-13-25, relating to
21 Schedule I controlled substances, by revising subparagraph (C) as follows:

22 "(C) ~~Reserved~~ Methiopropamine;"

23 **SECTION 4.**

24 Said chapter is further amended by revising division (12)(L)(ii) of Code Section 16-13-25,
25 relating to Schedule I controlled substances, as follows:

26 "(ii) By substitution at the 3-position with a ~~cyclic or acyclic~~ an alkyl, ~~substitution or~~
27 ~~alkoxy, or cyclic~~ substitution; ~~or~~"

28 **SECTION 5.**

29 Said chapter is further amended in paragraph (13) of Code Section 16-13-25, relating to
30 Schedule I controlled substances, by adding a new division to subparagraph (E) to read as
31 follows:

32 "(v) Amine;"

33 **SECTION 6.**

34 Said chapter is further amended in subsection (a) of Code Section 16-13-28, relating to
35 Schedule IV controlled substances, by adding new paragraphs to read as follows:

36 "(14.5) Fluclotizolam;"

37 "(30.17) Serdexmethylphenidate;"

38 **SECTION 7.**

39 Said chapter is further amended in subsection (b) of Code Section 16-13-71, relating to the
40 definition of dangerous drug, by adding new paragraphs to read as follows:

41 "(17.03) Aducanumab-avwa;"

42 "(21.3) Allogeneic cultured keratinocytes and dermal fibroblasts in murine
43 collagen-dsat;"

44 "(21.5) Allogeneic processed thymus tissue-agdc;"

45 "(44.1) Amivantamab-vmjw;"

46 "(52.7) Anifrolumab-fnia;"

47 "(65.8) Asciminib;"

48 "(67.3) Asparaginase erwinia chrysanthemi (recombinant)-rywn;"

49 "(68.135) Atogepant;"

50 "(69.03) Avacopan;"

51 "(69.05) Avalglucosidase alfa-ngpt;"

52 "(69.07) Avanafil;"

53 "(81.2) Belumosudil;"

54 "(81.4) Belzutifan;"

55 "(122.6) Cabotegravir;"

56 "(146.3) Casimersen;"

57 "(217.2) COVID-19 Vaccine, mRNA;"

58 "(240.95) Dasiglucagon;"

59 "(317.45) Dostarlimab-gxly;"

60 "(331.035) Efgartigimod alfa-fcab;"

61 "(350.5) Estetrol;"

62 "(380.35) Evinacumab-dgnb;"

- 63 "(383.47) Fexinidazole:"
64 "(386.63) Finasteride:"
65 "(386.65) Finerenone:"
66 "(406.45) Fosdenopterin:"
67 "(438.5) Hepatitis vaccine:"
68 "(463.3) Ibrexafungerp:"
69 "(464.17) Idecabtagene vicleucel:"
70 "(472.4) Infigratinib:"
71 "(525.7) Lisocabtagene maraleucel:"
72 "(529.07) Lonapegsomatropin-tcgd:"
73 "(529.08) Loncastuximab tesirine-lpyl:"
74 "(540.2) Maralixibat:"
75 "(540.45) Maribavir:"
76 "(622.6) Mobocertinib:"
77 "(661.57) Odevixibat:"
78 "(681.33) Pafolacianine:"
79 "(692.505) Pegcetacoplan:"
80 "(731.05) Piflufolastat F 18:"
81 "(732.1) Pimecrolimus:"
82 "(732.2) Pimozide:"
83 "(742.03) Plasminogen, human-tvmh:"
84 "(752.15) Ponesimod:"
85 "(845.25) Rpeginterferon alfa-2b-njft:"
86 "(851.035) Samidorphan:"
87 "(883.6) Sotorasib:"
88 "(931.82) Tepotinib:"
89 "(943.4) Tezepelumab-ekko:"

90 "(965.3) Tick-borne encephalitis vaccine;"

91 "(967.63) Tisotumab vedotin-tftv;"

92 "(967.67) Tivozanib;"

93 "(990.05) Trilaciclib;"

94 "(1018.7) Umbralisib;"

95 "(1028.5) Vericiguat;"

96 "(1030.6) Viloxazine;"

97 "(1037.2) Voclosporin;"

98 "(1037.83) Vosoritide;"

99 **SECTION 8.**

100 Said chapter is further amended in Code Section 16-13-71, relating to the definition of
101 dangerous drug, by revising paragraphs (19.3), (72.4), (276), (386.3), (731.1), and (732.9)
102 and repealing paragraph (69.1) of subsection (b) as follows:

103 "(19.3) Alcaftadine – See exceptions;"

104 "(72.4) Azelastine – See exceptions;"

105 "(276) Reserved Difelikefalin;"

106 "(386.3) Finasteride Reserved;"

107 "(731.1) Pimozide Reserved;"

108 "(732.9) Pimecrolimus Reserved;"

109 **SECTION 9.**

110 Said chapter is further amended in subsection (c) of Code Section 16-13-71, relating to
111 definition of dangerous drug, by adding new paragraphs to read as follows:

112 "(0.7) Alcaftadine – when used in a concentration of 0.25 percent or less in an
113 ophthalmic solution;"

114 "(1.5) Azelastine hydrochloride – when used in a concentration of 0.15 percent or less
115 in a nasal spray or nasal solution;"

116 **SECTION 10.**

117 This Act shall become effective upon its approval by the Governor or upon its becoming law
118 without such approval.

119 **SECTION 11.**

120 All laws and parts of laws in conflict with this Act are repealed.